Thao Tran

Doctor by training, patient by plot twist. I decode labs by day, care for toddler by night. Fighting autoimmune diseases with facts, flair, & flares.

[Jiha Lee @JihaRheum]

In the CLOSE-UP study of UPA in RA
- 61% in remission with responses sustained to 24 mo
- Benefit consistent irrespective of prior DMARD use
- No new safety signals

@RheumNow #ACR25 Abstract#2281

[Richard Conway @RichardPAConway]

Eder et al. Deucravacitinib in PsA from POETYK-PsA stuides. Male and female patients had similar response rates at week 16. ACR 20 57% vs 51%, ACR50 27% vs 27%, ACR70 12% vs 10%, MDA 24% vs 20%. @RheumNow #ACR25 Abstr#2356

[David Liew @drdavidliew]

After melanoma, should RA patients stop DMARDs?

These VA data (n=644) showed no mortality signal, and trending to survival benefit with b/tsDMARDs

Provisos over methotrexate, invasive disease etc, but don’t hold off treating the RA because of melanoma

#ACR25 ABST2237 @RheumNow

[Jiha Lee @JihaRheum]

Sjögren’s, decoded by Ab -->ESSDAI domains:
• anti-SSA → glandular
• anti-Ro52 / SCL70 → biologic activity
• anti-nucleosome → pulmonary
• anti-histone → pulmonary + cutaneous

Distinct serologic–ESSDAI patterns may guide monitoring and management

@RheumNow #ACR25 A#2295

[David Liew @drdavidliew]

Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card.

We’re not exactly overwhelmed with proven options for FM, the unmet need is so great, so the more, the better.

#ACR25 FDA session @RheumNow

[Thao Tran @thaotranmd]

@drdavidliew @RheumNow Excited for this!

[David Liew @drdavidliew]

@RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile

#ACR25 FDA Update @RheumNow

[David Liew @drdavidliew]

@RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too.

#ACR25 FDA Update @RheumNow

[sheila @RHEUMarampa]

Dr. John Stone on IgG4RD
⬆️ common in males
⬆️internal organ involvement
🔸Mimics cancer
🔸Indolence makes it dangerous —-> organ complications

Diagnosis highly dependent on the rheumatologist based on clinical features, serologies, imaging & pathological data
#ACR25 @Rheumnow

[David Liew @drdavidliew]

There’s all sorts of products out there. Who knows, ‘Reuma King’ or ‘Contra Reumas’ might do something, but that’s probably all the fraudulent hidden dexamethasone inside…

Beware+++
#ACR25 FDA Update @RheumNow

[Brian Jaros, MD @Dr_Brian_MD]

What's new in sjogren's?

Promising phase III data of telitacicept (dual BLyS + APRIL neutralization)

Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose

Similar rates of adverse events

@RheumNow #ACR25 Abst LB11

[sheila @RHEUMarampa]

Predictors of retinopathy progression after HCQ discontinued?

In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c

Age - significant assoc'n with progression

✳️monitor toxicity more closely esp in older pts
#ACR25 @RheumNow Abs2444

[David Liew @drdavidliew]

DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario cohort.

We’re getting better at finding a balance with DMARDs that is safe for both mother and baby. Blanket resistance is harmful

#ACR25 ABST2627 @RheumNow

[Aurelie Najm @AurelieRheumo]

We often see patients with MTX lab abnormalities but How frequent is MTX toxicity?

Retrospective study 2500pts
Rochester Epidemiology Project cohort

60% w/ ever lab abnormalities, but 4% attributed to MTX 0.87/100 patient year
Organ injury event 0.02/100 patient year = 5 in total

Out of the 5, 2 only (so less than 50%) were detected by biology...
And 7000 hours of MD and RN time

Is monitoring in its current form really necessary?
@RheumNow
#ACR25 #ABSTRACT2567

[Dr. John Cush @RheumNow]

Sleep Apnea in Psoriatic Arthritis – A Wake Up Call

Fatigue is one of the most disabling symptoms in psoriatic arthritis (PsA), yet its causes are often underexplored. At #ACR25, Abstract #0549, a possible hidden contributor was studied: obstructive sleep apnea (OSA). In a cohort of 247 PsA patients, researchers found that 50% had diagnosed OSA by PSG, a rate notably higher than in the general population.

https://t.co/K2nQ2xRx60

[Association of Women in Rheumatology @AWIRGROUP]

TOMORROW: AWIR’s HS in Rheumatology Summit!

Secure your spot for Rheumatology and Dermatology specialty insights, latest evidence, practical tools, priority Web App access, and free CME credits. Don’t miss strategies you can apply in the clinic immediately - register now.

https://t.co/NdV4AY9v7X

[Thao Tran @thaotranmd]

What happens if a rheumatologist gets called something else? 🤔 Will it change what we do? Not really. In fact, sometimes the simplest labels, like ‘arthritis doctor,’ can actually bring us closer to our patients. #rheumatology #arthritis Read more: https://t.co/J3H6H35x9v

[Association of Women in Rheumatology @AWIRGROUP]

Why Rheum-Derm Collaboration is Key for Complex Skin Disease: 
- The problem: HS often amplifies underlying systemic immune dysregulation but remains under-recognized, delaying diagnosis and compounding disease burden. 
- The solution: Early detection and timely treatment are critical to halt disease progression and improve long-term outcomes. 
- The approach: Coordinated, multidisciplinary collaboration between rheumatology and dermatology to streamline recognition and management of these conditions. 

Join AWIR’s Virtual Summit today and take your patient care to the next level! Discover how to manage HS in rheumatology patients, understand their inflammatory overlap, explore new targeted therapies, and learn strategies to collaborate across disciplines for personalized, impactful care.

Plus, earn 1.5 FREE CME/MOC credits while engaging in rich, case-based discussions led by experts in dermatology and rheumatology. 

Register today to attend virtually from anywhere or join a local Watch Party near you: https://t.co/NdV4AY9v7X

[Dr. John Cush @RheumNow]

Telitacicept, a BLyS (BAFF)/APRIL dual-target fusion drug, announced it has met the primary endpoint in its Phase III clinical trial in treating primary Sjögren's syndrome (pSS) in China. Primary endpoint was the change in ESSDAI score at Week 24. https://t.co/afOgpGLdV1

[Association of Women in Rheumatology @AWIRGROUP]

Don’t Stream Alone—Join an AWIR Watch Party Near You!
Get national-level education and local networking at AWIR's Virtual Summit + Watch Parties.

Why attend?
- Learn key data on and new therapies for HS & vitiligo in rheumatology patients.
- Connect face-to-face with rheumatology professionals in your area.
- Participate in live peer-to-peer discussions during the national livestream.
- Plus, you can earn 1.5 CME/MOC credits for free!

World-class content. Real-world connections. One powerful experience.

Register now: https://t.co/NdV4AY9v7X